In vivo dendritic cell reprogramming for cancer immunotherapy
Science · 18.10.2024 · 386 (6719)
DOI: 10.1126/science.adn9083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 18.10.2024. Verfasst von Ervin Ascic und 25 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, 221 84 Lund, Sweden. Hauptthemen laut MEDLINE: Cellular Reprogramming, Dendritic Cells, Immunotherapy, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Research Council.
Abstract (Originalsprache)
Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells; induced tumor regressions; and established long-term systemic immunity in multiple mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, 221 84 Lund, Sweden.
- Wallenberg Centre for Molecular Medicine at Lund University, 221 84 Lund, Sweden.
- Asgard Therapeutics AB, Medicon Village, 223 81 Lund, Sweden.
- InSphero AG, 8952 Schlieren, Switzerland.
- Department of Oncology, National Center of Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, 2730 Herlev, Denmark.
- Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
ORCID-Profile: Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Maria de Rosa Torres, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart Greiff, Irina Agarkova, Inge Marie Svane, Cristiana F Pires, Fábio F Rosa, Carlos-Filipe Pereira
Förderung
- European Research Council
Zitieren
APA
Ascic, E., Åkerström, F., Sreekumar Nair, M., Rosa, A., Kurochkin, I., Zimmermannova, O., Catena, X., Rotankova, N., Veser, C., Rudnik, M., Ballocci, T., Schärer, T., Huang, X., de Rosa Torres, M., Renaud, E., Velasco Santiago, M., Met, Ö., Askmyr, D., Lindstedt, M., …, & Pereira, C. F. (2024). In vivo dendritic cell reprogramming for cancer immunotherapy. Science, 386(6719). https://doi.org/10.1126/science.adn9083
Vancouver
Ascic E, Åkerström F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science. 2024;386(6719). doi:10.1126/science.adn9083
BibTeX
@article{Ascic2024,
author = {Ascic, Ervin and Åkerström, Fritiof and Sreekumar Nair, Malavika and Rosa, André and Kurochkin, Ilia and Zimmermannova, Olga and Catena, Xavier and Rotankova, Nadezhda and Veser, Charlotte and Rudnik, Michal and Ballocci, Tommaso and Schärer, Tiffany and Huang, Xiaoli and de Rosa Torres, Maria and Renaud, Emilie and Velasco Santiago, Marta and Met, Özcan and Askmyr, David and Lindstedt, Malin and Greiff, Lennart and Ligeon, Laure-Anne and Agarkova, Irina and Svane, Inge Marie and Pires, Cristiana F and Rosa, Fábio F and Pereira, Carlos-Filipe},
title = {In vivo dendritic cell reprogramming for cancer immunotherapy},
journal = {Science},
year = {2024},
volume = {386},
number = {6719},
doi = {10.1126/science.adn9083}
}
EUVIMED